This technology leverages phosphodiesterase 5 (PDE5) inhibitors—such as tadalafil and sildenafil—in combination with the standard of care to treat gastric adenocarcinomas (GAC). The use of PDE5 inhibitors has the potential to enhance immune response and treatment outcomes with a well-established safety profile. Background: Gastric adenocarcinoma (GAC) presents significant treatment challenges, with a 5-year survival rate near 18% despite advances combining chemotherapy, immune checkpoint inhibitors, and HER2-targeted therapies. There is a clear unmet need for precision-guided immune therapies with improved safety. The neoadjuvant use of cGMP-dependent phosphodiesterase inhibitors (PDE5 inhibitors) like tadalafil and sildenafil may boost immunotherapy effectiveness while maintaining a low toxicity profile. Applications:
Advantages: